Labcorp announced it received CE-IVDR marking from European regulators for its PGDx Elio Tissue Complete assay, a next-generation sequencing test for pan-solid tumor profiling. This regulatory advance complements its FDA clearance from 2020 and enables broader availability of the assay for investigational and clinical trial use through Labcorp’s Geneva lab. The platform detects tumor-associated variants across 505 genes from formalin-fixed tissue and aims to provide a high-quality, regulatory-compliant option for biopharma partners facilitating global oncology drug development.